DPO-1

Overview

DPO-1 is a potent Kv1.5 and Kv1.3 ( EC 50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca 2+ influx in Ca 2+ -depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium ( HY-B2130A ) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5 -mediated K + efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Depression | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Hypertension | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Potassium Channel | Products > Signaling Pathways > Calcium Channel | Products > Signaling Pathways > NOD-like Receptor (NLR) | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-100712
• CAS No.: 43077-30-1
• Molecular Formula: C22H29OP
• Molecular Weight: 340.44
• Purity: 98.39%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source